Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
15 Nicotinamide Riboside Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerNAD Supplementation for Brain Health in Aging
Oklahoma City, Oklahoma
This trial tests if taking Nicotinamide Riboside (NR), a form of Vitamin B3, can improve brain health and memory in older adults aged 60-85 by boosting a molecule called NAD that helps with energy and cell health. Nicotinamide Riboside (NR) is a precursor to NAD+, which has been identified as a promising treatment strategy for age-related cognitive decline and other conditions.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:60 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Disease, Major Psychiatric, Others
Must Not Be Taking:NAD Enhancers
214 Participants Needed
Nicotinamide Riboside for Sarcopenia
Kansas City, Missouri
Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, COPD, Others
144 Participants Needed
Nicotinamide Riboside for High Blood Pressure
Boulder, Colorado
Aging is the primary risk factor for cardiovascular diseases (CVD), the number one cause of death in developed societies. Systolic blood pressure (SBP) increase with age and is a key intermediary factor linking aging to increased CVD risk. The primary mechanisms underlying the age-associated increase in SBP is stiffening of the large elastic arteries, which is mediated by increases in oxidative stress, inflammation, and vascular smooth muscle tone. Regular caloric restriction is effective at lowering SBP in middle-aged and older adults; however, adherence to caloric restriction is poor and may be detrimental to normal weight older adults due to reduced skeletal muscle mass and bone mineral density. Therefore, identification of more practical alternative interventions that mimic the beneficial effects of caloric restriction, with stronger adherence and less risk of adverse consequences, is of significant biomedical importance.
Nicotinamide riboside is a naturally occurring precursor of nicotinamide adenine dinucleotide (NAD+), a critical mediator of the beneficial effects of caloric restriction, and therefore a novel caloric restriction mimetic compound. We recently completed the first pilot study of nicotinamide riboside supplementation in healthy middle-aged and older adults and demonstrated that 6 weeks of supplementation decreased systolic blood pressure (SBP) by 8 mmHg in individuals with baseline SBP of 120-139 mmHg (elevated SBP/stage 1 hypertension) compared with placebo, and lowered arterial stiffness, a strong independent predictor of CVD and related morbidity and mortality.
As a next translational step, we will conduct a randomized, placebo-controlled, double-blind clinical trial to further assess the safety and efficacy of oral nicotinamide riboside (3 months vs placebo) for decreasing SBP and arterial stiffness in middle-aged and older men and women with SBP between 120 and 139 mmHg at baseline.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Chronic Kidney Disease, Cancer, Others
Must Not Be Taking:Antihypertensives
118 Participants Needed
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Not Listed
48 Participants Needed
NR Supplementation + Exercise for Cancer Survivors
Memphis, Tennessee
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.
The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:10 - 30
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Kidney Disease, Liver Disease, Others
Must Not Be Taking:Statins, Glucocorticoids, NAD+ Precursors
80 Participants Needed
Vitamin B3 Derivative for Mitochondrial Myopathy
Rochester, Minnesota
This trial is testing a vitamin B3 supplement called Nicotinamide Riboside (NR) in adults who have muscle problems due to mitochondrial myopathy. The supplement aims to help their muscle cells produce more energy. Researchers hope this will improve symptoms in these patients. Nicotinamide riboside (NR), a form of vitamin B3, has been shown to boost NAD(+) levels and improve mitochondrial function.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Renal Failure, Others
34 Participants Needed
Nicotinamide Riboside for Cognitive Impairment and Sleep Quality
Buffalo, New York
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia
50 Participants Needed
Nicotinamide Riboside for Systemic Lupus Erythematosus (SLE)
Bethesda, Maryland
Study Description:
Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinucleotide (NAD)+ boosting with nicotinamide riboside blunts type 1 IFN activation in-vivo in monocytes of healthy subjects and ex-vivo in SLE subjects. These findings support the proposal of the hypothesis that NAD+ boosting by NR supplementation will modulate metabolic pathways in lupus and blunt type 1 interferon signaling. Moreover, as type 1 interferon drives endothelial dysfunction, linked to increased cardiovascular risk, the effect of NR on endothelial function will be examined.
Objectives:
Primary Objective: Evaluate the effect of NR vs. placebo on immunometabolic and inflammatory remodeling in female SLE subjects:
Exploratory Objective: Compare and characterize myeloid cell bioenergetic and immunometabolic profiles in healthy control and SLE female subjects
Endpoints:
Primary Endpoint:
The primary end point will be to assess the effect of NR on blunting type I IFN signaling by measuring monocytic secretion of IFN-beta secretion compared to baseline in response to placebo vs. NR supplemented in SLE study subjects.
Exploratory Endpoints:
Healthy control vs. SLE subjects:
* Compare type I IFN transcript profiles in monocytes and neutrophils at baseline and in response to activation.
* Assess cell bioenergetics including: 1) monocyte and neutrophil metabolic flux mass spectroscopy of 13C-glucose and 13Cglutamine analysis to investigate their metabolic fates; (iii) Mitochondrial oxygen consumption (using glucose, amino acid, and fatty acid substrates) and glycolysis rates.
SLE baseline vs. NR/placebo supplementation:
Baseline vs. 6 weeks of NR/placebo:
-Assess effect of NR on bioenergetics by measuring steady-state metabolite levels comparing changes in placebo vs. NR groups in monocytes and neutrophils.
Baseline vs. 12 weeks of NR/placebo:
* Whole blood NAD+ levels (batched and measured at the end of study enrollment period)
* Explore effects of NR on gene regulation using monocyte and neutrophils by RNA-seq and chromatin remodeling analysis.
* Determine the effect of NR vs placebo on endothelial dysfunction in SLE subjects
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Active Renal, CNS Disease, Pregnancy, Others
Must Not Be Taking:Biologics, Cyclophosphamide, IVIG, Others
78 Participants Needed
Nicotinamide Riboside + Ketogenic Diet for Fatty Liver Disease
Bethesda, Maryland
Background:
At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem.
Objective:
To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat.
Eligibility:
Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults with maturity-onset diabetes of the young type 2 (MODY2) are also needed.
Design:
Participants with diabetes will have 1 screening visit and a 9-day clinic stay. Healthy volunteers will have 1 screening visit and 2 clinic stays of 1 to 2 weeks each.
During screening, all participants will have a physical exam with blood and urine tests. They will have their heart rhythm measured while riding a gym bike.
NR is a pill taken by mouth. Only healthy volunteers will take the NR, for 14 days at a time, during 1 clinic stay. During their other stay, they will take placebos; these are pills that look like the study supplement but contain no NR.
During each clinic stay, all participants will eat a normal American diet. Then they will eat a ketogenic low-carb diet for 5 days.
Participants will have many tests, including:
Sleeping every night and having two 24-hour stays in a special room that measures the gases their body uses and produces.
Drinking a high-fat shake, then remaining seated for 5 hours while their blood and breath are monitored.
Having a substance injected into the arm and remaining seated for 3 hours while their blood is measured.
Wearing monitors to measure their activity levels. Another monitor will measure their blood glucose levels.
Having imaging scans.
...
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Liver Disease, Non-MODY2 Diabetes, Heart Failure, Others
Must Not Be Taking:Diet Medications
100 Participants Needed
Nicotinamide Riboside for Gulf War Syndrome
Sarasota, Florida
This trial tests whether taking Nicotinamide Riboside (NR), a form of vitamin B3, can help veterans with Gulf War Illness (GWI). GWI causes symptoms like fatigue and pain, possibly due to low energy levels in cells. NR aims to increase a molecule called NAD+ in the blood, which is crucial for cell energy production. The goal is to see if this can improve the health and well-being of these veterans. Nicotinamide Riboside (NR) is a newly discovered nicotinamide adenine dinucleotide (NAD+) precursor vitamin, recognized as safe for use in foods and dietary supplements.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:47 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Nursing, Hypertension, Renal Failure, Others
Must Not Be Taking:NR Supplements
52 Participants Needed
This trial studies the effect of exercise and a vitamin-like supplement on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes. Participants will either do regular home exercise or do the same exercise while also taking a supplement similar to vitamin B3. The goal is to see if these interventions can improve their muscle health and how their body handles insulin.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Not Listed
20 Participants Needed
Zinc + Nicotinamide Riboside for Pulmonary Fibrosis
Los Angeles, California
The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Asthma, Tuberculosis, Cancer, Others
Must Be Taking:IPF Standard Care
60 Participants Needed
NAD+ Precursor (NR) + Exercise for Ataxia
Philadelphia, Pennsylvania
Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on VO2max and Si in Friedreich's Ataxia (FA).
The primary objective of this research is to measure the effect of combination administration (NR + exercise) on aerobic capacity (VO2max) in FA. A key secondary objective is to measure the effect of combination administration (NR + exercise) on glucose homeostasis (Si) in FA.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:10 - 40
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Anemia, Kidney Disease, Others
Must Not Be Taking:Statins, Supraphysiologic Steroids
80 Participants Needed
Nicotinamide Riboside for Heart Failure
Seattle, Washington
This trial tests whether a vitamin B3 supplement called nicotinamide riboside can help patients with severe heart failure by improving their cell energy production and reducing inflammation. The study focuses on patients undergoing heart surgery to implant a device that helps their heart pump blood.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cirrhosis, Severe Renal Disease, Untreated Thyroid, Others
32 Participants Needed
Nicotinamide Riboside for Alzheimer's Disease
Belmont, Massachusetts
This trial is testing nicotinamide riboside (NR), a form of vitamin B3, to see if it can help people with early memory problems or mild Alzheimer's. The idea is that NR can boost a molecule called NAD+ in the brain, which helps cells produce energy and reduces stress. Researchers hope this will improve brain function in these patients. Nicotinamide riboside (NR) is a precursor to NAD+ and has shown potential in improving learning and memory in animal models of dementia.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:55 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychotic Disorder, Stroke, Cancer, Others
Must Not Be Taking:Benzodiazepines, Barbiturates, Opiates, Others
50 Participants Needed
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Zinc + Nicotinamide Riboside for Pulmonary Fibrosis, Nicotinamide Riboside for Systemic Lupus Erythematosus (SLE) and Nicotinamide Riboside + Ketogenic Diet for Fatty Liver Disease to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.